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Background: Bevacizumab combination therapy is among the most frequently used treat-
ments in recurrent glioblastoma and patients who achieve response to bevacizumab
have improved survival as well as quality of life. Accordingly, the aim of this study was
to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma
patients.
Methods: The study included a total of 82 recurrent glioblastoma patients treated with bev-
acizumab combination therapy whom were both response and biomarker evaluable. Gene
expression of tumor tissue was analyzed by using a customized NanoString platform
covering 800 genes. Candidate gene predictors associated with response were analyzed
by multivariate logistic and Cox regression analysis.
Results: Two genes were independently associated with response: Low expression of angio-
tensinogen (2-fold decrease in AGT; OR ¼ 2.44; 95% CI: 1.45e4.17; P ¼ 0.0009) and high
expression of a HLA class II gene (2-fold increase in HLA-DQA1; OR ¼ 1.22; 95% CI: 1.01e1.47;
P ¼ 0.04). These two genes were included in a model that is able predict response to bev-
acizumab combination therapy in clinical practice. When stratified for a validated prog-
nostic index, the predictive model for response was significantly associated with improved
overall survival.growth factor A; C-index, concordance index; AGT, angiotensinogen; HLA-DQA1, human
1; IDH1, isocitrate dehydrogenase 1.
iation Biology, The Finsen Center, Rigshospitalet, Section 6321, Blegdamsvej 9, DK-2100
; fax: þ45 35 45 63 01.
(T. Urup).
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ochemical Societies. Published by Elsevier B.V. All rights reserved.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 1 6 0e1 1 6 8 1161Conclusion: Two genes (low angiotensinogen and high HLA-class II expression) were pre-
dictive for bevacizumab response and were included in a predictive model for response.
This model can be used in clinical practice to identify patients who will benefit from
bevacizumab combination therapy.
ª 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction monotherapy was not administered at our center. EligibilityGlioblastoma is the most common primary malignant brain
tumor in adults. Despite aggressive standard treatment,
including maximal surgical resection and post-operative
radiochemotherapy with temozolomide concomitantly and
as maintenance, newly diagnosed patients have a median
overall survival (OS) of less than 15 months (Stupp et al.,
2005). At tumor recurrence no standard treatment is available
and most known options have limited clinical effect.
Glioblastoma is characterized by increased angiogenesis
and abnormal network of blood vessels. Anti-angiogenic
agents inhibiting vascular endothelial growth factor A
(VEGF) have been shown to normalize the tumor vasculature
and improve blood flow, emphasizing the potential value of
combining anti-angiogenic therapy with drugs targeting the
tumor (Batchelor et al., 2013; Lu-Emerson et al., 2015). Howev-
er, recent results from the first randomized phase III trial
investigating chemotherapy with or without the VEGF-
antibody bevacizumab did not demonstrate any difference
in OS when considering the whole group of recurrent glioblas-
toma patients (Wick et al., 2015). Still, approximately 30% of
patients achieve durable bevacizumab response and this
group of patients has demonstrated improved survival as
well as quality of life (Henriksson et al., 2011; Huang et al.,
2016; Moller et al., 2012). This underscores the importance of
identifying patients who will benefit from bevacizumab com-
bination therapy. To date, no validated predictive tumor
markers of a durable bevacizumab response have been identi-
fied. By analyzing gene expression profiles of glioblastoma pa-
tient tumors, the aim of this study was to identify predictive
factors for bevacizumab response in recurrent glioblastoma
patients.2. Patients and methods
2.1. Patients
All patients with pathologically confirmed glioblastoma (WHO
grade IV) who were treated at recurrence with bevacizumab
plus irinotecan between May 2005 and December 2011 at Rig-
shospitalet were assessed for eligibility. During this period,
bevacizumab (10mg/kg) and irinotecan (125mg/m2), adminis-
tered every two weeks, could be prescribed to all recurrent
glioblastoma patients in WHO performance status 0e2 ac-
cording to a published treatment protocol (Poulsen et al.,
2009). Alternatively, both agents were combined with cetuxi-
mab in a phase 2 trial (Hasselbalch et al., 2010). Bevacizumabcriteria for this study were response evaluability and
biomarker assessable tissue from the time of glioblastoma
diagnosis. The criteria are specified in Section 2.2e2.4 and a
REMARK diagram is shown in Supplementary Figure S1. The
studywas conducted in accordancewith the Helsinki Declara-
tion and was approved by the Danish Ethical Committee (H-2-
2012-069).
2.2. Clinical follow-up
According to the treatment protocol, patients had to have
measurable progressive disease by contrast-enhanced MRI af-
ter standard therapy and be at least 4 weeks from prior
chemotherapy and 3 months from completion of radiation
therapy. For patients who had undergone relapse surgery a
post-surgical MRI was performed prior to treatment initiation.
Clinical follow-up was performed every 4-weeks and MRI
every 8 weeks. Treatment response was evaluated based on
the RANO criteria (Wen et al., 2010). Patients were categorized
according to their best response; patients who achieved com-
plete response (CR) or partial response (PR) were classified as
responders, while patients with stable disease (SD) or progres-
sive disease (PD) were classified as non-responders. Patients
not evaluable by MRI at first response evaluation (week 8)
due to early toxicity, progression or death were classified as
non-evaluable and excluded.
2.3. Sample acquisition and RNA preparation
A total of 90 archived formalin-fixed, paraffin-embedded tis-
sue samples from time of initial glioblastoma diagnosis
were collected and freshly cut sections (5 microns) were
sent to HistogeneX, Belgium, and stored at 2e8 C. Tissue re-
view was conducted by a pathologist blinded to identifiers
and clinical outcome, and areas containing representative tu-
mor cells were marked on hematoxylin and eosin-stained
slides. Five samples with insufficient tumor tissue area for
RNA analysis were excluded. Tumors were microdissected
to enrich tumor cell RNA in the gene expression analyses.
RNA was extracted using the High Pure RNA Paraffin Isolation
kit (Roche, Ca. No. 03 270 289 001) and RNA extracts were
stored at 80 C.
2.4. Gene expression data generation
The platform consisted of 800 genes selected by Genentech
using a custom code set for the NanoString gene expression
platform (NanoString Technologies, Seattle, WA) (Geiss et al.,
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 1 6 0e1 1 6 811622008). Genes were selected from the literature to allow glio-
blastoma molecular subtype classification according to Phil-
lips’ classifier (Phillips et al., 2006) and to cover genes
regulating angiogenesis, immune system and other
glioblastoma-related cancer hallmarks. Analyses were per-
formed using the software R version 3.1 (R Development
Core Team, Vienna, Austria, http://www.R-project.org). Raw
counts for 85 tumor samples were log2 transformed and
normalized to 8 housekeeping genes recommended by Genen-
tech and previously used on the AvaGlio dataset (Sandmann
et al., 2015). The normalization procedure is described in Sup-
plementary Method 1. Based on the distribution of normalized
counts, 3 outlier samples were identified and removed from
further analysis, leaving 82 evaluable samples. Subtype labels
were assigned to tumor samples by Genentech blinded to clin-
ical outcome using the 31 gene classifier previously trained on
the AVAglio dataset (Sandmann et al., 2015).Table 1 e Patient characteristics.
Total (n ¼ 82)
Gender, n (%)
Male 51 (62)
Female 31 (38)
Age, years (range)
Median 56 (23e71)
WHO performance status, n (%)2.5. Immunohistochemistry
Immunohistochemical analysis was conducted on 5 micron
thick formalin-fixed, paraffin-embedded tissue sections.
Following deparaffinization and protease treatment immuno-
staining was performed using the OptiView DAB IHC v4 Proto-
col (v1.00.0108) and the BenchMark ULTRA IHC staining
Module (Ventana Medical System, Tucson, AZ, USA). The pri-
mary antibodies used were anti-HLA-DQA1 (dilution 1:150,
Abcam, EPR7300), anti-HLA-DR (dilution 1:2000, DAKO, TAL
1B5), anti-AGT (dilution 1:1500, LS Bioscience, LS-B6575),
anti-CD31 (ready-to-use, Ventana Medical System, JC70),
anti-collagen-IV (dilution 1:20, DAKO, CIV 22) and anti-SMA
(ready-to-use, DAKO, 1A4).0 34 (42)
1 37 (45)
2 11 (13)
Prior lines of chemotherapy, n (%)
1 73 (89)
2 9 (11)
Multifocal disease, n (%)
Yes 21 (26)
No 61 (74)
Corticosteroid use, n (%)a
Yes 61 (74)
No 21 (26)
Neurocognitive deficit, n (%)
Yes 43 (52)
No 39 (48)
Bevacizumab combination therapy, n (%)
Irinotecan 67 (82)
Irinotecan and cetuximab 15 (18)
Response, n (%)
Response (CR þ PR) 29 (35)
Stable disease 42 (51)
Progressive disease 11 (14)
Median progression-free survival, months 5.3
Responders 10.9
Non-responders 3.9
Median overall survival, months 8.2
Responders 13.8
Non-responders 7.5
AbbreviationsCR, complete response; PR, partial response.
a Prednisolone >10 mg.2.6. Statistical analysis
Survival probabilities (PFS and OS) were estimated with the
KaplaneMeier method. Welch’s test was performed to iden-
tify differentially expressed genes between groups and signif-
icant genes with a fold-change >1.5 were considered.
Treatment response was estimated by employing logistic
regression (modelling the probability of response) and the re-
sults presented by odds ratios with 95% confidence intervals
(95% CI) and the area under the receiver operating character-
istic curve. The Cox proportional hazards model was used
for modelling survival endpoints and results are presented
as hazard ratios (HR) with 95% CI. Continues covariates were
log transformed (log base 2) for analysis. Assessment of the
model assumptions was done using HosmereLemeshow test
and martingale residuals. Factors associated with response
with P-values below 0.20 in univariate analysis were
considered for multivariate analysis. Penalized maximum
likelihood estimation was utilized for multivariate analysis
and concordance indices (C-index) was calculated as a
measure of discrimination (Harrell, Jr. et al., 1996). Five-fold
cross-validation was applied to the analysis of response in or-
der to assess the estimated model. P-values < 0.05 were
considered significant. Calculations were performed using
SPSS (v19.0, IBM Corp., Armonk, NY), R version 3.1 and SAS
(v9.3, SAS institute, Cary, NC).3. Results
3.1. Patient characteristics
Of the 158 patients registered as receiving bevacizumab com-
bination therapy at the time of relapse, 82 patients were
response and biomarker evaluable (REMARK diagram,
Supplementary Figure S1). Patient characteristics and clinical
outcomes for the 82 patients are shown in Table 1. Response
was observed in 29 patients (35%) of whom 22 (76%) achieved
response at first treatment evaluation. After progression on
bevacizumab combination treatment, 13 patients underwent
surgical resection and 10 patients received various types of
experimental treatments. Two patients were alive at the end
of follow-up and all had progressed (median-follow-up: 8.3
months, range: 2e69 months).
3.2. Prognostic factors
Univariate analysis was performed to test if previously identi-
fied prognostic factors, shown in Table 1, were associatedwith
Step 2. Identification of candidate genes:
Welch’s t-test, CR+PR vs. PD 
(P < 0.05; median fold change ≥ 1.5) 
Step 2       
9 genes
Step 3. Identification of genes associated 
with response:  
Univariate analysis of CR+PR vs. SD+PD 
(P < 0.20) 
Step 4. Identification of predictive factors 
for response:  
Multivariate analysis of CR+PR vs. SD+PD 
(P < 0.05) 
Step 3       
5 genes
Step 4       
2 genes
Step 1 
792 genes
Step 1. Pre-processing of data:
Log2 transformation and normalization to 8 
house-keeping genes 
Figure 1 e Flowchart for identification of differentially expressed
genes associated with bevacizumab response. The number of genes
shown in the right dotted box denotes the number of genes identified
according to analytical steps.
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an impact on response. None of these factors were associated
with response. The gene expression profiles of glioblastomas
treated with and without cetuximab were comparable and
only 3 genes were significantly differentially expressed be-
tween these two groups (IFI27, IFIT3 up-regulated and POSTN
down-regulated in the cetuximab group). None of these genes
were associated with response. In addition, we tested a
recently established and validated prognostic index for recur-
rent glioblastoma patients treated with bevacizumab and iri-
notecan (Urup et al., 2016). This index consists of 8
prognostic groups according to all possible combinations of
the presence or absence of 3 independent prognostic factors:
corticosteroid use (10 mg Prednisolone), neurocognitive
deficit (minor) and multifocal disease. When applied to the
current study cohort, the index was by univariate analysis
significantly associated with PFS (P ¼ 0.01) and OS (P ¼ 0.005)
but it was not associated with response (P ¼ 0.45).
3.3. Molecular subtypes
Out of 82 samples, 27 were classified as proneural and 32 as
the mesenchymal subtype. As illustrated in Supplementary
Figure S2, the remaining 23 samples, categorized as prolifera-
tive or unclassified subtype, separated poorly from the pro-
neural and mesenchymal subtypes. Consequently, it was
decided to analyze only the two robust subtypes as dichoto-
mized variables: Proneural vs. non-proneural and mesen-
chymal vs. non-mesenchymal. By univariate analysis,
shown in Supplementary Table S1, the two subtypes showed
no association with response. Furthermore, no association
with PFS or OS was observed in univariate analysis, nor
when stratified for the prognostic index described above.
3.4. Identification of biomarkers associated with
bevacizumab response
As shown in Figure 1, after pre-processing data, three steps
were utilized to identify differentially expressed genes associ-
ated with treatment response. First, samples were divided
into three groups according to best response: Response
(CR þ PR), stable disease (SD) and progressive disease (PD).
To identify candidate genes differentially expressed between
the two most extreme groups (response and PD) and to
address unequal variance and unequal sample sizes of the
groups, a Welch’s t-test was performed (Step 2). Out of 792
genes, 9 genes were found significantly differentially
expressedwith amedian fold change>1.5. Among the 9 genes
shown in Supplementary Table S2, two genes were signifi-
cantly up-regulated (BEST3 and RTN1) and one was down-
regulated (ERBB2) in the proneural subtype compared to the
mesenchymal subtype. The 9 genes were screened for associ-
ation with response (CR þ PR) versus non-response (SD þ PD)
by univariate analysis (Step 3). As shown in Supplementary
Table S3, 5 genes were found associated with response
(P < 0.20) and these were tested by multivariate analysis
(Step 4, Supplementary Table S4). This analysis presented
angiotensinogen (AGT ) and a HLA class II gene (human leuko-
cyte antigen complex class II DQ alpha 1, HLA-DQA1) as being
the most interesting markers associated with response.3.5. Predictors for response
Table 2 summarizes the finalmultivariatemodel for response.
Indeed, low gene expression of angiotensinogen (2-fold
decrease: OR ¼ 2.44; 95% CI: 1.45e4.17; P ¼ 0.0009) and high
expression of HLA class II (DQA1) (2-fold increase: OR ¼ 1.22;
95% CI: 1.01e1.47; P ¼ 0.04) were significantly associated
with an increased likelihood of response. None of the remain-
ing gene candidates were significantly associated with
response when added to the model. The final model for
response had a high C-index of 0.78.
3.6. Association of predictors with PFS and OS
The two genes predictive for response were analyzed for asso-
ciation with PFS and OS. By univariate analysis, low gene
expression of angiotensinogen was significantly associated
with prolonged PFS (P ¼ 0.01) and OS (P < 0.01), and high
expression of HLA class II (DQA1) was significantly associated
with prolonged OS (P ¼ 0.03) but was not associated with PFS
(P¼ 0.16). Bymultivariate analysis stratified for the prognostic
index (Table 2), low expression of angiotensinogen was inde-
pendently associated with prolonged PFS (2-fold decrease:
HR ¼ 0.75; 95% CI: 0.59e0.94; P ¼ 0.01) and OS (2-fold decrease:
HR ¼ 0.70; 95% CI: 0.54e0.94; P ¼ 0.005), while HLA class II
(DQA1) expression did not significantly influence PFS or OS.
The C-indices for the PFS and OS model were 0.67 and 0.68,
respectively.
3.7. Clinical predictive model for response
In order to develop a model which in clinical practice can be
used to predict bevacizumab response, themultivariatemodel
for response was used to determine a cut point for angiotensi-
nogen and HLA class II (DQA1) gene expression. Due to
Table 2 eMultivariate analysis of response, PFS and OS.
Gene expression Response OR (95% CI) PFSa HR (95% CI) OSa HR (95% CI)
Angiotensinogen (2-fold decrease) 2.44 (1.45e4.17)
P ¼ 0.0009
0.75 (0.59e0.94)
P ¼ 0.01
0.70 (0.54e0.94)
P ¼ 0.005
HLA-class II (DQA1) (2-fold increase) 1.22 (1.01e1.47)
P ¼ 0.04
0.96 (0.88e1.04)
P ¼ 0.31
0.95 (0.87e1.04)
P ¼ 0.27
C-index 0.78 0.67 0.68
Note: The prognostic index was not associated with response (P ¼ 0.45).; Abbreviations: HLA-class II (DQA1), human leukocyte antigen complex
class II DQ alpha 1, HLA-DQA1.
a Stratified for a prognostic index consisting of three independent prognostic factors: Corticosteroid use, neurocognitive deficit and multifocal
disease.
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 1 6 0e1 1 6 81164limitations and difficulties in response assessment, we prior-
itized a high specificity in preference to a high sensitivity in
order to increase the likelihood of identifying patients not
responding and not benefitting from bevacizumab treatment.
Accordingly, a model able to predict bevacizumab response
with a sensitivity of 66% at a specificity of 80% was estab-
lished. In Figure 2, the linear curve is the gene expression
threshold for angiotensinogen and HLA class II (DQA1) sepa-
rating responders from patients not responding, illustrating
that the gene expression threshold for each gene increases
as a function of the other. In clinical practice this meansFigure 2 e Predictive model for response to bevacizumab. The linear curv
complex class II DQ alpha 1 (DCA1) gene expression, separating respond
80%. X- and Y-axis represent gene expression count data for the two genesthat a patient with a relatively high expression of angiotensi-
nogen (e.g. 900) is predicted to achieve response only if HLA
class II (DQA1) is also relatively high (e.g. 1500), while another
patient with the same expression of angiotensinogen but a
lower expression of HLA class II (DQA1) will not respond to
bevacizumab. The cross validation procedure confirmed the
estimated model for response, both covariates were signifi-
cant in all cases and the C-index was 0.75 for the test
component.
When stratified according to the prognostic index, patients
who according to the predictive model were predicted toe is the threshold for angiotensinogen and human leukocyte antigen
ers from non-responders with a sensitivity of 66% and a specificity of
normalized to reference genes.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 1 6 0e1 1 6 8 1165respond had a borderline significantly longer PFS (P¼ 0.06) and
significantly longer OS (P < 0.01) compared to patients pre-
dicted not to respond. This association with OS remained sig-
nificant when patients progressing at the first response
evaluation were excluded from the analysis, indicating that
the association of the model with OS is not due to including
early progressors.
3.8. Immunohistochemistry
To examine the protein expression intensity and localization
of angiotensinogen and HLA class-II proteins in glioblastoma,
immunohistochemical analysis was performed on 10 tumor
samples. These were the 5 showing the highest and the 5
showing the lowest gene expression levels of angiotensinogen
on the NanoString platform. Staining for HLA-class II (DQA1)
and HLA-DR as a control resulted in a similar granular cyto-
plasmic staining of macrophages and microglia located peri-
vascular, around necrosis and diffusely in the stroma to a
varying degree. There were no obvious differences in amountFigure 3 e Immunohistochemistry of glioblastomas with low and high angio
shown for two low (AeB) and two high (CeD) angiotensinogen gene expr
angiotensinogen stains are shown below for low (EeF) and high (GeH) ang
stained for CD31 (IeL), Collagen IV (MeP) and smooth muscle actin (Qe
MLN, Q-R) and high (K-L, OeP, ST) angiotensinogen gene expression.and location of HLA expressing cells across the samples with
differing angiotensinogen expression (Supplementary
Figure S3).
As shown in Figure 3, angiotensinogen demonstrated a
more diffuse staining in both reactive astrocytes, macro-
phages, microglia, glial tumor cells, endothelial cells and the
extracellular matrix. The cellular staining was either cyto-
plasmic, nuclear or both. The intensity was varying between
samples and intratumoral heterogeneity was most pro-
nounced between malignant proliferating vessels and tumor
cells. In glioblastomas with low gene expression, the staining
intensity in tumor cells was mostly cytoplasmic and lower
compared to tumor cells of glioblastomas with high angioten-
sinogen gene expression, which had a more pronounced
staining in both cytoplasm and nucleus. The proliferating ves-
sels in low angiotensinogen expressing glioblastomas seemed
less compact, less fibrotic, and consisted of a mixture of posi-
tive and negative endothelial cells. In contrast, vessels in high
angiotensinogen expressing tumors were more compact,
fibrotic, proliferative and had smaller lumina.tensinogen expression. Overviews (350) of angiotensinogen stains are
essing tumors. Tumor blood vessels (3400) of corresponding
iotensinogen expression. Serial sections of corresponding samples were
T) and blood vessels (3400) are shown below for tumors with low (I-J,
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 1 6 0e1 1 6 81166To characterize the observed differences of the vasculature
in more detail, we stained for endothelial cells (CD31),
Collagen IV and smooth muscle actin (SMA). As shown in
Figure 3, low angiotensinogen gene expression was associated
with a more normal CD31 stain of endothelial cells of vessels
(IeJ), Collagen IV (MN) and SMA (QeR) were located around
the vascular lumen. Thesemore normal vessels were also pre-
sent in tumors expressing high angiotensinogen. However, in
the tumors with high angiotensinogen expression the vascu-
lature was more abnormal. Some of these highly abnormal
vessels appeared highly viable with CD31 located on endothe-
lial luminal cells (Figure 3K), hyperplastic with greater SMA
(Figure 3O) and withmore compact Collagen IV (Figure 3S) im-
munostaining. Other vessels were characterized by diffuse
CD31 staining (Figure 3L), reduced Collagen IV (Figure 3P)
and fragmented SMA (Figure 3T). Both of these vascular phe-
notypes were present in the tumors with high angiotensino-
gen expression and the tumors also expressed the more
normal variant described in the low angiotensinogen express-
ing tumors.
Taken together, the vasculature variedwithin and between
the tumors. However, the vasculature of the tumors with high
angiotensinogen expression showed a greater variability of
the vascular phenotype, had smaller vessel lumina and
appeared more hyperplastic and more proliferative compared
to tumors expressing low angiotensinogen.4. Discussion
In this retrospective study of 82 recurrent glioblastoma pa-
tients treated with bevacizumab combination therapy, gene
expression profiles of tumor tissue from the initial glioblas-
toma diagnosis were analyzed with the aim of identifying pre-
dictive factors for bevacizumab response. By analyzing
candidate genes differentially expressed between responders
and patients with early progressive disease, the expression of
two genes were found independently associated with a favor-
able response to bevacizumab therapy: These were low gene
expression of angiotensinogen (AGT ) and high gene expres-
sion of HLA class II (HLA-DQA1). Both were included in a clin-
ically relevant model that can predict whether a patient is
likely or not to respond to bevacizumab combination therapy.
In support of our findings, angiotensinogen has previously
been found overexpressed in tumors of metastatic colorectal
cancer patients not responding to bevacizumab combination
therapy (Martin et al., 2014). In addition, it has been shown
that angiotensinogen and all components of the renin-
angiotensin system, including the main effector peptide
angiotensin-II, are expressed in glioblastomas (Juillerat-
Jeanneret et al., 2004).
The renin-angiotensin system appears to exert dual effects
on the vasculature, as angiotensinogen has demonstrated
anti-angiogenic signaling (Celerier et al., 2002), while
angiotensin-II has been observed to induce angiogenesis
(Arrieta et al., 2008; Paul et al., 2006). Here we found that
increasing angiotensinogen expression was associated with
a higher level of vascular proliferation, suggesting an
angiotensin-II dominating effect on the vasculature. Further-
more, high expression levels of angiotensinogen wasassociated with a more abnormal vessel architecture, charac-
terized by excessive vascular remodeling and greater numbers
blood vessels with reduced vessel lumina. These findings are
also in line with angiotensin-II signaling which stimulates
vascular remodeling (Lacolley et al., 2012). Of note, angiotensi-
nogen gene expression was not correlated to VEGF gene
expression. Accordingly, we hypothesize that locally pro-
duced angiotensinogen and angiotensin-II induce an
abnormal and poorly perfused tumor vasculature which
cannot sufficiently be normalized by bevacizumab therapy.
Angiotensin-II inhibition has demonstrated a steroid-
sparring and anti-edema effect in glioblastoma patients
(Carpentier et al., 2012). In addition, preclinical and retrospec-
tive studies suggest that combination of angiotensin-II inhibi-
tion and anti-angiogenic therapy at least has an additive effect
(Keizman et al., 2011; McKay et al., 2015; Stylianopoulos and
Jain, 2013). Consequently, we are retrospectively investigating
the efficacy and safety of this combination treatment in recur-
rent glioblastoma patients. This and other clinical studies,
including an ongoing phase III trial with angiotensin-II inhibi-
tion in combination with standard therapy (NCT01805453),
will provide information on whether angiotensin-II inhibition
should be administered to glioblastoma patients.
HLA-class II receptors are expressed on antigen presenting
cells and by immunohistochemistry analysis expression was
observed on microglia and macrophages. A possible explana-
tion for the association of high HLA-class II gene expression
and bevacizumab response is that HLA class II is up-
regulated on local antigen presenting cells, which in turn
directly activates and maintains a cytotoxic anti-tumor im-
mune response. In such a scenario, bevacizumab treatment
might induce an active immune response which is otherwise
often reported to be skewed towards an immunosuppressive
profile in glioblastoma (Nduom et al., 2015). Indeed, accumu-
lating data indicate that anti-angiogenic agents activate
anti-tumor immune cells and upon normalization of the
vasculature increase the number of these tumor infiltrating
immune cells (Huang et al., 2013). Accordingly, HLA-class II
expressionmay reflect an existing anti-tumor immune profile,
which in concert with bevacizumab-induced immune activa-
tion may explain the association of HLA-class II with a benefi-
cial effect of bevacizumab. Several clinical trials are currently
evaluating combinatorial regimens of bevacizumab with
different types of immunomodulating agents for glioblastoma
patients (Reardon et al., 2015).
The molecular subtypes in our cohort had no impact on
response, PFS or OS. Whether the proneural subtype (IDH1
wildtype) is a predictive factor for improved survival in beva-
cizumab treated glioblastoma patients, as suggested in the
AvaGlio dataset (Sandmann et al., 2015), remains to be vali-
dated in a randomized trial. However, as subtype assignment
has been shown to change following treatment and as a
consequence of intratumoral heterogeneity, a clinically rele-
vant subtype classification for recurrent glioblastoma has
yet to be established (Patel et al., 2014; Phillips et al., 2006).
In summary, we identified low gene expression of angio-
tensinogen and high expression of a HLA-class II gene (HLA-
DQA1) as independent predictors of bevacizumab response.
Both genes are according to the literature involved in response
and resistance mechanisms to anti-angiogenic combination
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 1 6 0e1 1 6 8 1167therapies and we are currently testing these hypotheses pre-
clinically as well as clinically. Based on the two identified
genes we established a model which in clinical practice has
the potential to predict bevacizumab response in recurrent
glioblastoma patients. If validated, this model will contribute
to identifying patients who will or will not benefit from beva-
cizumab combination therapy.Funding
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